Skip to main content
Main menu
About
Our Mission
Donors
Board of Directors
Advisory Boards
Staff
Careers
FAQ
Annual Report
Louder Than TB
Why New TB Drugs?
Global Pandemic
Inadequate Treatment
Antimicrobial Resistance
Maternal and Child Health
Cycle of Poverty
R&D
Scientific Vision
Pipeline
Discovery
Developing New Regimens
Engaging Communities
Access
Our Commitment
Understanding the TB Market
Child-friendly medicines
Pretomanid and BPaL
Pathways to Access BPaL
News
Latest News
Publications
Voices of TB
Research Papers
20 Years of Impact
Donate
Search form
Search
Our Pipeline
Portfolio
Compounds
Regimens
Partners
Trials
Phase 1
TBAJ-587
TBAJ-587 / Diarylquinoline
ERA4TB
TBAJ-876
TBAJ-876
TBI-223
TBI-223 / Oxazolidinone
Institute of Materia Medica
Phase 2
Sutezolid
Sutezolid / Oxazolidinone
Bill & Melinda Gates Medical Research Institute
TBA-7371
TBA-7371 / DprE1 Inhibitor
Foundation for Neglected Disease Research, Bill & Melinda Gates Medical Research Institute
Phase 3
SimpliciTB
Bedaquiline / Pretomanid / Moxifloxacin / Pyrazinamide
BPaMZ
PanACEA, Radboud University, Viatris
ZeNix
Bedaquiline / Pretomanid / Linezolid
BPaL
Viatris
Phase 4
Pediatric Formulation Development
Pretomanid
Viatris
Optimized First-Line Drugs in Children >5kg
Ethambutol
Pyrazinamide
Isoniazid
